Easton Capital Partners

WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional office in New York, New York. Founded in 2010, it specializes in providing wellness programs to healthcare providers, including rural health clinics and integrated delivery networks. The company focuses on administering Medicare Annual Wellness Visits, offering clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors, preventative goals, and measurable data. WellTrackONE supports healthcare professionals by scheduling, screening, and documenting wellness visits, while also providing critical data for accountable care organizations and helping payers maintain compliance with clinical indicators and quality measures. Through its customized wellness solutions, WellTrackONE aims to enhance patient care and improve health outcomes for Medicare patients across the United States.

Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional office in New York, New York. Founded in 2010, it specializes in providing wellness programs to healthcare providers, including rural health clinics and integrated delivery networks. The company focuses on administering Medicare Annual Wellness Visits, offering clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors, preventative goals, and measurable data. WellTrackONE supports healthcare professionals by scheduling, screening, and documenting wellness visits, while also providing critical data for accountable care organizations and helping payers maintain compliance with clinical indicators and quality measures. Through its customized wellness solutions, WellTrackONE aims to enhance patient care and improve health outcomes for Medicare patients across the United States.

Wildflower Health, Inc. is a health engagement platform based in San Francisco, California, that provides smartphone-based health programs aimed at connecting healthcare payers with families across the United States. Founded in 2012, the company offers a maternity program called Due Date Plus, which addresses engagement challenges by assisting women in early pregnancy and facilitating connections with care managers. Additionally, Wildflower Health provides GROW, a family health program that focuses on mothers and encompasses pediatric and family health. Its platform delivers personalized health milestones based on age and gender, along with resources such as on-device messaging, appointment reminders, health risk assessments, and provider referrals. By utilizing user-centered design and technology, Wildflower Health aims to empower families to make informed healthcare decisions and support their individual health needs over time.

PerceptiMed, Inc. specializes in manufacturing and marketing medication-verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. The company's key offerings include the IdentRx, an automated device that ensures accurate verification of prescription pills, and IdentRx Remote, a software solution that facilitates remote verification of dispensed medications. Additionally, PerceptiMed provides MedPass, which aims to further reduce errors in pill administration, and ScripClip, an electronic tagging system. The company's innovative VeriFill technology enhances the precision of prescription fulfillment by delivering 100% verification of drug, dosage, and manufacturer, thereby improving safety and efficiency in medication management. Founded in 2011, PerceptiMed is headquartered in Mountain View, California, and serves clients throughout the United States.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

Medikly, Inc. is a digital marketing platform that assists healthcare marketers in effectively reaching and engaging physicians. Founded in 2009 and based in Jersey City, New Jersey, the company offers a comprehensive solution that allows pharmaceutical brands to form deeper connections with physicians by leveraging actionable insights derived from physician intelligence. Medikly's platform serves as an operating system for healthcare marketers, enabling them to continuously collect, analyze, and manage data from various digital channels. In addition to its core platform, Medikly provides services such as campaign execution, modification, and measurement, along with consulting, support, and training, all aimed at enhancing the efficiency of marketing efforts in the healthcare sector.

Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.

electroCore, Inc. is a commercial stage medical device company based in Basking Ridge, New Jersey, specializing in bioelectronic medicine. The company focuses on the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies, primarily aimed at enhancing patient outcomes in neurology. Its flagship product, gammaCore, is a prescription-only device designed for the acute treatment of pain associated with migraine and episodic cluster headaches, as well as for the preventive treatment of these conditions in adult patients. The gammaCore Sapphire is a rechargeable and reloadable handheld system that can be prescribed on a monthly basis for multi-year use. Founded in 2005, electroCore aims to address various neurological conditions through its innovative therapeutic platform.

MedCPU Inc. develops real-time enterprise decision support software aimed at enhancing clinical care in hospitals across the United States. Founded in 2008 and based in New York, the company offers the medCPU Advisor platform, which integrates patient profiles derived from both structured and unstructured data. Its innovative Advisor Button technology captures and analyzes clinical information from clinicians’ free-text notes, dictations, and structured documentation entered into electronic medical records (EMRs). This analysis is conducted against an extensive library of medical content, allowing the platform to generate precise, real-time prompts for care consideration, as well as providing clinical and compliance guidance. MedCPU's focus is on improving decision-making processes in healthcare settings through advanced data integration and analysis.

Respiratory Motion, Inc. is a medical device company based in Waltham, Massachusetts, that specializes in the development and commercialization of respiratory monitoring devices. Founded in 2011, the company offers the ExSpiron, a point-of-care device designed to non-invasively measure critical respiratory parameters such as minute ventilation, tidal volume, and respiratory rate. With FDA clearance for its continuous monitoring systems, Respiratory Motion provides healthcare professionals with real-time data that enhances patient safety and helps in the early detection of respiratory collapse across various patient populations and clinical settings.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

SOLX, Inc. is a Waltham, Massachusetts-based company that specializes in developing devices and treatments for glaucoma therapy. Founded in 2000, the company focuses on creating innovative solutions to reduce, manage, and measure intraocular pressure (IOP) in the human eye. One of its key offerings is the SOLX Gold Shunt, a minimally invasive device designed for the surgical treatment of glaucoma. Through its product portfolio, SOLX aims to improve patient outcomes in glaucoma management.

Precise Light Surgical, Inc. specializes in developing innovative tissue resection solutions for microsurgical procedures. Founded in 2008 and based in California, the company focuses on providing less invasive surgical options that prioritize the preservation of critical anatomy, thereby reducing surgical risks and enhancing patient outcomes. Its technology, which employs flash vaporization, offers precise control for the removal of delicate tissues while safeguarding nerves and blood vessels. This approach is applicable across various medical fields, including plastic surgery, ear, nose, and throat (ENT) surgery, and neurosurgery. By improving surgical precision and reducing recovery time, Precise Light Surgical aims to enhance the overall efficiency and effectiveness of surgical interventions.

Comprehend Systems, Inc. is a provider of cloud-based continuous quality solutions for clinical operations, founded in 2010 and headquartered in Redwood City, California. The company offers a suite of clinical intelligence applications designed to enhance the speed, safety, and quality of clinical trials. These solutions support clinical operations executives, data managers, and medical monitors by delivering actionable insights for portfolio monitoring, CRO oversight, risk management, and collaboration across various teams and sites. Comprehend's tools aim to streamline the clinical trial process, improving overall performance and risk assessment throughout the research lifecycle. As of August 2019, Comprehend operates as a subsidiary of Saama Technologies, Inc.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

Medikly, Inc. is a digital marketing platform that assists healthcare marketers in effectively reaching and engaging physicians. Founded in 2009 and based in Jersey City, New Jersey, the company offers a comprehensive solution that allows pharmaceutical brands to form deeper connections with physicians by leveraging actionable insights derived from physician intelligence. Medikly's platform serves as an operating system for healthcare marketers, enabling them to continuously collect, analyze, and manage data from various digital channels. In addition to its core platform, Medikly provides services such as campaign execution, modification, and measurement, along with consulting, support, and training, all aimed at enhancing the efficiency of marketing efforts in the healthcare sector.

Within3, Inc. is a digital collaboration solutions provider focused on the healthcare, pharmaceutical, and life sciences sectors. Established in 2004 and headquartered in Lakewood, Ohio, with an additional location in the United Kingdom, the company specializes in facilitating engagement among healthcare professionals worldwide. Its technology supports various initiatives, including virtual advisory boards, steering committees, clinical trial design and operations, and internal training programs. Within3's platform allows organizations to engage physicians, nurses, payers, and patients in a compliant manner, utilizing social technologies to create private, regulatory-compliant environments for collaboration. The company aims to enhance the interaction and collaboration within the healthcare ecosystem to improve outcomes and streamline processes.

PerceptiMed, Inc. specializes in manufacturing and marketing medication-verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. The company's key offerings include the IdentRx, an automated device that ensures accurate verification of prescription pills, and IdentRx Remote, a software solution that facilitates remote verification of dispensed medications. Additionally, PerceptiMed provides MedPass, which aims to further reduce errors in pill administration, and ScripClip, an electronic tagging system. The company's innovative VeriFill technology enhances the precision of prescription fulfillment by delivering 100% verification of drug, dosage, and manufacturer, thereby improving safety and efficiency in medication management. Founded in 2011, PerceptiMed is headquartered in Mountain View, California, and serves clients throughout the United States.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. Established in 2010, the company is advancing its lead biologic compounds, including RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby reducing kidney damage and interferon activation. Additionally, Resolve Therapeutics is progressing RSLV-133, a bi-specific Fc-nuclease fusion protein that integrates dual nuclease activities into a single therapeutic molecule. The company's research is rooted in significant discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a commitment to enhancing the quality of life for patients affected by these challenging conditions.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Achronix Semiconductor Corp. is a privately held fabless company based in Santa Clara, California, specializing in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, is built on Intel's advanced 22nm process technology and incorporates fully integrated hard IP protocol functions, making it suitable for communications applications. Achronix also offers Speedcore eFPGA IP for integration into customers' system-on-chip designs, as well as a comprehensive design tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. The company's products cater to various markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security sectors. Achronix sells its products through distributors across North America, Europe, Israel, China, and Russia. Founded in 2004, Achronix has research and development facilities in both Santa Clara and Bangalore, India.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

SOLX, Inc. is a Waltham, Massachusetts-based company that specializes in developing devices and treatments for glaucoma therapy. Founded in 2000, the company focuses on creating innovative solutions to reduce, manage, and measure intraocular pressure (IOP) in the human eye. One of its key offerings is the SOLX Gold Shunt, a minimally invasive device designed for the surgical treatment of glaucoma. Through its product portfolio, SOLX aims to improve patient outcomes in glaucoma management.

Within3, Inc. is a digital collaboration solutions provider focused on the healthcare, pharmaceutical, and life sciences sectors. Established in 2004 and headquartered in Lakewood, Ohio, with an additional location in the United Kingdom, the company specializes in facilitating engagement among healthcare professionals worldwide. Its technology supports various initiatives, including virtual advisory boards, steering committees, clinical trial design and operations, and internal training programs. Within3's platform allows organizations to engage physicians, nurses, payers, and patients in a compliant manner, utilizing social technologies to create private, regulatory-compliant environments for collaboration. The company aims to enhance the interaction and collaboration within the healthcare ecosystem to improve outcomes and streamline processes.

EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, specializing in the development of neuromodulation therapies utilizing its proprietary Transdermal Stimulation (TranStim) technology. This innovative approach aims to provide effective treatment for conditions such as overactive bladder and urinary incontinence by delivering electric pulses that facilitate neuromodulation. Founded in 2006, EMKinetics focuses on advancing its therapies to improve patient outcomes in managing these health issues.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. Established in 2010, the company is advancing its lead biologic compounds, including RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby reducing kidney damage and interferon activation. Additionally, Resolve Therapeutics is progressing RSLV-133, a bi-specific Fc-nuclease fusion protein that integrates dual nuclease activities into a single therapeutic molecule. The company's research is rooted in significant discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a commitment to enhancing the quality of life for patients affected by these challenging conditions.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

Autonet Mobile, Inc. is a technology company that specializes in internet-based telematics and applications services aimed at enhancing vehicle connectivity in motion. Founded in 2005 and headquartered in Santa Rosa, California, the company offers a suite of products known as Dealer Connect, which automates vehicle health scans, lot tracking, and customer appointment scheduling for automotive dealers. For consumers, Autonet Mobile provides features such as 24/7 WiFi access, vehicle health monitoring, and driver safety applications. The company’s platform serves as a real-time diagnostic and reporting tool, alerting users to routine maintenance needs and transforming standard vehicles into connected cars. Autonet Mobile has established partnerships with several major automotive manufacturers, further solidifying its position in the industry. The company also offers installation, activation, setup, and customer support services for its products. It operates as a subsidiary of Lear Corporation.

Format Dynamics specializes in enhancing the integration of online advertising with print media by optimizing how web pages are printed. The company develops tools that allow advertisers to create new ad inventory by transforming printed web pages into visually appealing formats resembling magazines. This innovation enables advertisers to attach specific printable information and offers directly to onscreen advertisements, thereby expanding revenue opportunities. By improving the user experience and providing targeted advertising solutions, Format Dynamics facilitates a seamless transition from digital content to print, ultimately benefiting both advertisers and consumers.

CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, specializing in the development of neuromodulation therapies utilizing its proprietary Transdermal Stimulation (TranStim) technology. This innovative approach aims to provide effective treatment for conditions such as overactive bladder and urinary incontinence by delivering electric pulses that facilitate neuromodulation. Founded in 2006, EMKinetics focuses on advancing its therapies to improve patient outcomes in managing these health issues.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

Coapt Systems, Inc. specializes in the design, development, and manufacturing of bio-absorbable implants intended for soft tissue fixation in facial cosmetic surgery. Its product offerings include various fixation devices such as the ENDOTINE Forehead 3.0 and ENDOTINE Midface ST 4.5, which are employed in procedures like forehead lifts, brow lifts, and midface suspensions. The company also provides surgical instruments and tools, including insertion kits and manual drills, to facilitate the use of its implants. Coapt Systems aims to support surgeons in achieving effective and secure tissue fixation during surgical procedures, enhancing outcomes for patients undergoing cosmetic interventions.

CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

PlaySpan is a prominent provider of monetization solutions for online games, virtual worlds, and social networks. The company specializes in developing a digital goods commerce and micropayment platform that enables game publishers and developers to generate revenue, attract new users, and enhance user loyalty. One of its key offerings is UltimatePay, a global payment solution that facilitates safe and convenient in-app purchases through over 85 payment methods across 180 countries. This service includes the Ultimate Game Card, a prepaid card available in more than 45,000 retail locations throughout North America and expanding internationally. Headquartered in Silicon Valley, PlaySpan also operates offices in Ohio, Virginia, and Mumbai. The company has received recognition for its contributions to the gaming industry, winning the 2009 OnHollywood Category Award for Best Gaming Company.

Achronix Semiconductor Corp. is a privately held fabless company based in Santa Clara, California, specializing in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, is built on Intel's advanced 22nm process technology and incorporates fully integrated hard IP protocol functions, making it suitable for communications applications. Achronix also offers Speedcore eFPGA IP for integration into customers' system-on-chip designs, as well as a comprehensive design tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. The company's products cater to various markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security sectors. Achronix sells its products through distributors across North America, Europe, Israel, China, and Russia. Founded in 2004, Achronix has research and development facilities in both Santa Clara and Bangalore, India.

Xoft, Inc. specializes in developing electronic brachytherapy (eBx) systems for radiation oncology applications. The company offers a range of products, including the Axxent Controller, which employs a miniaturized high dose rate X-ray source to deliver radiation directly to cancerous tumor beds. Other products include the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, Xoft provides various accessories such as physics accessory kits, personnel protective shields, and patient care kits, along with FlexiShield, designed to minimize radiation exposure to healthy tissues and organs. The company's products are primarily utilized in the treatment of early stage breast cancer, skin cancer, and endometrial cancer. Xoft distributes its offerings through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, the company was previously known as Xoft microTube, Inc. before rebranding in 2004.

PlaySpan is a prominent provider of monetization solutions for online games, virtual worlds, and social networks. The company specializes in developing a digital goods commerce and micropayment platform that enables game publishers and developers to generate revenue, attract new users, and enhance user loyalty. One of its key offerings is UltimatePay, a global payment solution that facilitates safe and convenient in-app purchases through over 85 payment methods across 180 countries. This service includes the Ultimate Game Card, a prepaid card available in more than 45,000 retail locations throughout North America and expanding internationally. Headquartered in Silicon Valley, PlaySpan also operates offices in Ohio, Virginia, and Mumbai. The company has received recognition for its contributions to the gaming industry, winning the 2009 OnHollywood Category Award for Best Gaming Company.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

WIRECOM Technologies is a French company with state-of-the-art technology and an experience of over 10 years. Committed to sustainable development and the fight against global warming, WIRECOM Technologies designs and develops solutions to optimise energy efficiency in buildings and residences

GoCrossCampus, initially the flagship product of GXStudios, was developed by a group of students from Yale and Columbia between 2007 and 2010. It emerged as a pioneering social gaming platform, engaging hundreds of thousands of college students in a rivalry-based game of territorial conquest. Players formed teams representing different colleges or affinity groups, competing to conquer each other's campuses through strategic gameplay that included real-time interactions and recruitment efforts. The game's popularity extended beyond college campuses, with GXStudios also creating GoCrossOffice, a variant designed for corporate team-building activities aimed at enhancing morale and communication within virtual workforces. Despite its initial success, the company faced challenges during the 2008-2009 recession, leading to the decision to wind down operations and license its intellectual property. The founders were part of the Yale Entrepreneurial Institute, which continues to support startup ventures today.

PlaySpan is a prominent provider of monetization solutions for online games, virtual worlds, and social networks. The company specializes in developing a digital goods commerce and micropayment platform that enables game publishers and developers to generate revenue, attract new users, and enhance user loyalty. One of its key offerings is UltimatePay, a global payment solution that facilitates safe and convenient in-app purchases through over 85 payment methods across 180 countries. This service includes the Ultimate Game Card, a prepaid card available in more than 45,000 retail locations throughout North America and expanding internationally. Headquartered in Silicon Valley, PlaySpan also operates offices in Ohio, Virginia, and Mumbai. The company has received recognition for its contributions to the gaming industry, winning the 2009 OnHollywood Category Award for Best Gaming Company.

IGA Worldwide is a leading provider of in-game advertising technology, specializing in delivering impactful advertising solutions without disrupting the gaming experience. The company operates its proprietary ad serving network, Radial, which enables advertisers to engage with consumers across various platforms, including PlayStation, PC, Nintendo Wii, and Xbox 360. IGA Worldwide combines extensive reach with high accountability, utilizing advanced metrics and technology to ensure effective ad placements and branded content within major video game franchises. Their innovative approach allows advertisers, developers, and publishers to target diverse audiences while enhancing the gaming experience.

Gentis is a company focused on developing minimally invasive biomaterials-based products aimed at treating early-stage degeneration of the spine. Founded in 2000 and headquartered in Wayne, Pennsylvania, the company's flagship product, DiscCell, is an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material designed to augment or replace the diseased nucleus pulposus of the spinal disc. This innovative solution helps patients prevent the recurrence of back or leg pain at the treatment site, addressing a significant need in spinal healthcare.

Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Lamina, a Westhampton, N.J.-based LED developer.

Xoft, Inc. specializes in developing electronic brachytherapy (eBx) systems for radiation oncology applications. The company offers a range of products, including the Axxent Controller, which employs a miniaturized high dose rate X-ray source to deliver radiation directly to cancerous tumor beds. Other products include the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, Xoft provides various accessories such as physics accessory kits, personnel protective shields, and patient care kits, along with FlexiShield, designed to minimize radiation exposure to healthy tissues and organs. The company's products are primarily utilized in the treatment of early stage breast cancer, skin cancer, and endometrial cancer. Xoft distributes its offerings through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, the company was previously known as Xoft microTube, Inc. before rebranding in 2004.

Coapt Systems, Inc. specializes in the design, development, and manufacturing of bio-absorbable implants intended for soft tissue fixation in facial cosmetic surgery. Its product offerings include various fixation devices such as the ENDOTINE Forehead 3.0 and ENDOTINE Midface ST 4.5, which are employed in procedures like forehead lifts, brow lifts, and midface suspensions. The company also provides surgical instruments and tools, including insertion kits and manual drills, to facilitate the use of its implants. Coapt Systems aims to support surgeons in achieving effective and secure tissue fixation during surgical procedures, enhancing outcomes for patients undergoing cosmetic interventions.

Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.

Trellis Bioscience LLC is a biotechnology company focused on discovering and developing human antibody therapeutics for infectious diseases and oncology. The company utilizes its proprietary CellSpot technology platform to identify and extract rare, naturally optimized antibodies from healthy human donor blood cells. This enables the development of therapeutic monoclonal antibodies targeting various infectious diseases and cancer immune checkpoints. Trellis aims to offer alternatives for patients facing challenges with conventional protein therapeutics, particularly in cases where the immune system may attack these treatments. Founded in 1998, Trellis Bioscience is headquartered in Redwood City, California.

Achronix Semiconductor Corp. is a privately held fabless company based in Santa Clara, California, specializing in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, is built on Intel's advanced 22nm process technology and incorporates fully integrated hard IP protocol functions, making it suitable for communications applications. Achronix also offers Speedcore eFPGA IP for integration into customers' system-on-chip designs, as well as a comprehensive design tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. The company's products cater to various markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security sectors. Achronix sells its products through distributors across North America, Europe, Israel, China, and Russia. Founded in 2004, Achronix has research and development facilities in both Santa Clara and Bangalore, India.

CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

Cardiovascular Systems, Inc., established in 1989, specializes in developing and marketing innovative medical technologies for treating peripheral and coronary artery diseases. The company's primary product line is its orbital atherectomy systems, which employ a diamond-coated crown to remove plaque from arteries above and below the knee. These catheter-based platforms are designed to tackle challenging disease states, including calcium buildup, which is particularly prevalent in peripheral artery disease (PAD) and coronary artery disease (CAD). Cardiovascular Systems generates most of its revenue through sales of these peripheral orbital atherectomy systems in the United States.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

IGA Worldwide is a leading provider of in-game advertising technology, specializing in delivering impactful advertising solutions without disrupting the gaming experience. The company operates its proprietary ad serving network, Radial, which enables advertisers to engage with consumers across various platforms, including PlayStation, PC, Nintendo Wii, and Xbox 360. IGA Worldwide combines extensive reach with high accountability, utilizing advanced metrics and technology to ensure effective ad placements and branded content within major video game franchises. Their innovative approach allows advertisers, developers, and publishers to target diverse audiences while enhancing the gaming experience.

Sonics is a leading provider of network-on-chip (NoC) technology, specializing in intelligent on-chip communications solutions for various applications, including home entertainment, wireless networking, and mobile devices. Established in 1996 and headquartered in Milpitas, California, the company offers a comprehensive portfolio of silicon-proven intellectual property (IP) that addresses the memory bottlenecks and data flow challenges associated with complex, high-speed system-on-chip (SoC) designs. By enabling heterogeneous, multi-core SoC architectures, Sonics integrates essential subsystems, such as security, power, and memory, to deliver high performance and low power consumption. Its innovative technology has facilitated the shipment of over 750 million units globally, positioning Sonics as a key player in the embedded market.

Bluebird bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on researching, developing, and commercializing gene therapies for severe genetic diseases and cancer. The company's gene therapy programs include LentiGlobin, aimed at treating β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing chimeric antigen receptor T (CAR T) cell therapies, specifically bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with several organizations, including Bristol-Myers Squibb and Regeneron Pharmaceuticals, to advance gene therapies in oncology and immune cell therapies. Additionally, bluebird bio collaborates with various partners to explore T cell receptor product candidates and in vivo genome editing treatments for genetic disorders. Established in 1992 and originally known as Genetix Pharmaceuticals, the company transitioned to its current name in 2010.

Sonics is a leading provider of network-on-chip (NoC) technology, specializing in intelligent on-chip communications solutions for various applications, including home entertainment, wireless networking, and mobile devices. Established in 1996 and headquartered in Milpitas, California, the company offers a comprehensive portfolio of silicon-proven intellectual property (IP) that addresses the memory bottlenecks and data flow challenges associated with complex, high-speed system-on-chip (SoC) designs. By enabling heterogeneous, multi-core SoC architectures, Sonics integrates essential subsystems, such as security, power, and memory, to deliver high performance and low power consumption. Its innovative technology has facilitated the shipment of over 750 million units globally, positioning Sonics as a key player in the embedded market.

CombinatoRx is a biotech company that develops medicines from synergistic combinations of approved drugs. The company has pushed into Phase 2 clinical trials a portfolio of drug candidates aimed at cancer and multiple immuno-inflammatory diseases. CombinatoRx Service Business was acquired by Horizon Discovery Group.

TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.

Zalicus Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing drug candidates for the treatment of pain and inflammation. The company leverages its expertise in ion-channel modulation to discover innovative therapeutics, both for its internal product pipelines and in collaboration with other entities. Zalicus invests significantly in research and development, including preclinical and clinical trials, while also pursuing intellectual property protection for its technologies and product candidates. One of its notable achievements includes the FDA approval of Exalgo, an extended-release formulation of hydromorphone HCl, which is indicated for managing moderate to severe pain in opioid-tolerant patients. The company was formed following the merger with Neuromed Pharmaceuticals in December 2009.

Conor MedSystems specializes in the development of controlled drug delivery technologies for vascular applications, primarily focusing on drug-eluting stents designed to treat coronary artery disease and restenosis. The company aims to enhance the effectiveness of vascular stents by incorporating mechanisms that allow for localized drug delivery to both coronary and peripheral vessels. Through its innovative approach, Conor MedSystems seeks to improve patient outcomes in the management of vascular conditions.

Renovis, Inc. is a biopharmaceutical company focused on the development of drugs for neurological diseases and disorders. The company is actively working on treatments for acute ischemic stroke, neuropathic pain, and acute post-operative pain. Utilizing a range of scientific disciplines, including molecular biology, medicinal chemistry, pharmacology, drug metabolism, toxicology, and informatics, Renovis aims to identify and select small molecule drug candidates that adhere to rigorous development standards.

Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders in the United States and internationally. The company’s primary product, Ampyra (dalfampridine), is an oral medication approved to enhance walking in patients with multiple sclerosis. Additionally, Acorda markets Inbrija, an inhalation powder for the treatment of OFF periods in individuals with Parkinson's disease. The company's pipeline includes rHIgM22, which has completed Phase I trials for multiple sclerosis, and Cimaglermin alfa, currently in Phase Ib trials for heart failure. Acorda has established a collaboration with Biogen for the development and commercialization of Ampyra. Founded in 1995 and based in Ardsley, New York, Acorda Therapeutics aims to improve the quality of life for those affected by neurological conditions.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Conor MedSystems specializes in the development of controlled drug delivery technologies for vascular applications, primarily focusing on drug-eluting stents designed to treat coronary artery disease and restenosis. The company aims to enhance the effectiveness of vascular stents by incorporating mechanisms that allow for localized drug delivery to both coronary and peripheral vessels. Through its innovative approach, Conor MedSystems seeks to improve patient outcomes in the management of vascular conditions.

Sonics is a leading provider of network-on-chip (NoC) technology, specializing in intelligent on-chip communications solutions for various applications, including home entertainment, wireless networking, and mobile devices. Established in 1996 and headquartered in Milpitas, California, the company offers a comprehensive portfolio of silicon-proven intellectual property (IP) that addresses the memory bottlenecks and data flow challenges associated with complex, high-speed system-on-chip (SoC) designs. By enabling heterogeneous, multi-core SoC architectures, Sonics integrates essential subsystems, such as security, power, and memory, to deliver high performance and low power consumption. Its innovative technology has facilitated the shipment of over 750 million units globally, positioning Sonics as a key player in the embedded market.

ModelWire specializes in software solutions tailored for the modeling and fashion industry, offering digital tools that enable model and talent agents to advertise and book their clients efficiently. The platform serves a diverse clientele, including advertising agencies, photographers, catalog publishers, and magazines, providing them with comprehensive resources for managing their operations. ModelWire's features encompass imaging, packaging, online booking, and invoicing, all accessible around the clock. As a global leader in online model management, ModelWire aims to enhance productivity and streamline workflows for agents, supporting their success in a competitive industry. ModelWire operates under the umbrella of Geyser Technologies.

Worldo, a vertical industry portal for commercial architectural interiors.

Jarg Corporation, founded in 1997 and based in Waltham, Massachusetts, specializes in developing innovative technologies for knowledge discovery applications. The company's Semantic Knowledge Indexing Platform allows software developers to create search engines that embed search terms in context, delivering qualitative search results. Jarg's distributed indexing platform leverages graph-based data and "semantic" content to enhance information retrieval, achieving both global recall and high precision. This technology significantly boosts productivity for knowledge workers and provides a competitive advantage for businesses. Jarg Corporation primarily licenses its platform to application developers, focusing on business-to-business portals and corporate intranets.